Last reviewed · How we verify
NCT05667181
The Application Value of da Vinci Linear Cutting Stapler SureForm in Robotic Anus Preserving Surgery for Rectal Cancer
NA trial testing Surform in Rectal Cancer in 276 participants. Completed in 29 December 2024.
11 November 2024
Quick facts
| Lead sponsor | Nanchang University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 276 |
| Start date | 29 December 2022 |
| Primary completion | 11 November 2024 |
| Estimated completion | 29 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Surform
Conditions studied
- Rectal Cancer — all drugs for Rectal Cancer →
- Robotic — all drugs for Robotic →
- Anastomotic Leak — all drugs for Anastomotic Leak →
- Laparoscopic — all drugs for Laparoscopic →
Sponsor
Nanchang University
Who can join
Adults 18 to 80, any sex, with Rectal Cancer or Robotic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anastomotic complications are serious complications after anus preserving surgery for rectal cancer,the instrument anastomosis technology are one of the factors that influence the occurrence of anastomotic complications after surgery,the laparoscopic linear cutting closure device used in robotic rectal cancer may increase the occurrence of anastomotic complications,but the robot linear cutting stapler (SureForm) may reduce the incidence of postoperative anastomotic complications due to the technical advantages,therefore,the aim of this study is to evaluate the impact of robotic linear cutting stapler SureForm and laparoscopic linear cutting stapler on the incidence of anastomotic complications after robotic rectal cancer anus preserving surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05667181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Cancer
Currently open trials in the same condition.
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
- NCT07501845 — Registry Maastro Applicator · recruiting
- NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
- NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting
Other Nanchang University trials
Trials by the same sponsor.
- NCT07528391 — Comorbidity-Oriented Primary Care and Integrated Management for Hypertension and Diabetes Mellitus · NA · not yet recruiting
- NCT06906952 — A Prospective Single-center Randomized Controlled Trial of Robotic Surgery With Transrectal Resection Specimens (NOSES-I · NA · enrolling by invitation
- NCT06681597 — Raspberry Ketone Intake Upregulates Circulating FGF21 and Induces Energy Expenditure in Humans · EARLY_PHASE1 · completed
- NCT06696729 — External Application of Mirabilite to Promote Recovery in Patients After Gastrointestinal Surgery · NA · completed
- NCT06454201 — Robotic Natural Orifice Specimen Extraction Surgery Compared to Robotic Assisted Surgery for Median Rectal Cancer · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05667181 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanchang University
- Last refreshed: 28 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05667181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing